Cancer News and Research

Latest Cancer News and Research

New studies reveal real economic and human costs of caring for cancer patients in Europe

New studies that reveal for the first time the real economic and human costs of caring for cancer patients in Europe will be presented during the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna.

29 Sep 2012

Synta announces results from ganetespib Phase 2b trial on NSCLC

Synta Pharmaceuticals Corp. today announced results from an interim analysis of the Phase 2b portion of the GALAXY trial, a global, randomized, multi-center Phase 2b/3 study designed to evaluate the efficacy and safety of the Company's lead Hsp90 inhibitor, ganetespib, as second-line treatment for advanced non-small cell lung cancer (NSCLC).

29 Sep 2012

Exelixis announces preliminary results from BRIM7 Phase Ib trial on BRAFV600 mutated MM

Exelixis, Inc. today announced preliminary results from BRIM7, an ongoing Phase Ib trial conducted by Roche and Genentech, Exelixis' collaborator and a member of the Roche Group, of the BRAF inhibitor (BRAFi) vemurafenib in combination with the MEK inhibitor GDC-0973 in patients with locally advanced/unresectable or metastatic melanoma carrying a BRAFV600 mutation.

29 Sep 2012

Study to look at whether maternal exercise during pregnancy can reduce risk of cancer in offspring

If a mother exercises during her pregnancy, will that benefit her children? Researchers at the University of Kentucky have initiated studies to look into the idea: a group from the UK Graduate Center for Nutritional Sciences has received a $100,000 grant from the National Institutes of Health to study whether maternal exercise during pregnancy can lead to a reduced risk of cancer in offspring.

29 Sep 2012

New trial data shows improvements in treatment of esophageal and gastrointestinal cancers

New trial data showing improvements in the treatment of esophageal and gastrointestinal cancers were released today at the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna.

29 Sep 2012

JAAD to publish Sensus Healthcare’s superficial radiotherapy study on non melanoma skin cancer

Sensus Healthcare is pleased to announce the acceptance and publication of the most comprehensive study to date on treating Non Melanoma Skin Cancer (NMSC) with superficial radiotherapy (SRT) in the Journal of the American Academy of Dermatology (JAAD).

29 Sep 2012

PLOS ONE journal releases report on validation of Falcon Genomics' Cancer BioChip System

The online journal PLOS ONE released a scientific report on the validation of Falcon Genomics' Cancer BioChip System (CBCS) as a tool for identifying inhibitors of breast cancer.

29 Sep 2012

State highlights: Free Calif. health care clinic a big draw; New Calif. law could mean mammogram alternatives

Many of the 4,800 people seeking care at the annual massive free clinic this weekend will become eligible for health insurance in 2014 when the national law takes effect. Organizers said raising awareness about the health care changes is crucial.

29 Sep 2012

Hackensack University Medical Center announces joint venture with community physicians and USPI

Hackensack University Medical Center has announced a joint venture partnership with community physicians and United Surgical Partners International (USPI) in the acquisition and operation of two ambulatory surgery centers (ASCs) in Bergen County: Hackensack Endoscopy Center (HEC) and Endoscopy Center of Bergen County (ECBC).

29 Sep 2012

Mount Sinai surgeon offers tips to prevent prostate cancer

World-renowned Mount Sinai robotic prostate surgeon, Dr. David Samadi, devotes much of his time to prostate cancer education domestically and internationally. "My SMART robotic prostate removal surgery saves lives, but what men really want to know is how to prevent prostate cancer in the first place," shares Dr. Samadi.

29 Sep 2012

AVEO submits tivozanib NDA with FDA for treatment of advanced renal cell carcinoma

AVEO Oncology and Astellas Pharma Inc. today announced that AVEO has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for tivozanib in patients with advanced renal cell carcinoma (RCC).

29 Sep 2012

FDA approves Abbott’s HUMIRA to treat ulcerative colitis

Abbott today announced that the U.S. Food and Drug Administration (FDA) has approved HUMIRA (adalimumab) for inducing and sustaining clinical remission in adult patients with moderately to severely active ulcerative colitis (UC) when certain other medicines have not worked well enough.

29 Sep 2012

ACS honors world-leader in robotic prostate surgery with 2012 Community Partner Award

At last night's Annual Prostate Cancer Awareness and Education Dinner, the American Cancer Society awarded Dr. David B. Samadi, world-leader in prostate cancer treatment and robotic prostate surgery, with the 2012 Community Partner Award. Through robotic surgery excellence, Dr. Samadi has successfully cured more than 4,000 men of prostate cancer.

29 Sep 2012

Wage disparities could limit success of health-care reform

A national study has found that earnings over the course of the careers of primary-care physicians averaged as much as $2.8 million less than the earnings of their specialist colleagues, potentially making primary care a less attractive choice for medical school graduates and exacerbating the already significant shortage of medical generalists.

29 Sep 2012

1-800-Oncologist launches Contributing Expert program

1-800-Oncologist, Inc. announced today the launch of its Contributing Expert program for oncology and radiology specialists. Members of 1-800-Oncologist's national Contributing Expert network are key opinion leaders in the cancer field that help translate medical news into information patients can understand and act upon.

29 Sep 2012

A.P. Pharma resubmits APF530 NDA with FDA for prevention of CINV

A.P. Pharma, Inc., a specialty pharmaceutical company, today announced that it has resubmitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its lead product candidate, APF530, for the prevention of acute- and delayed-onset chemotherapy-induced nausea and vomiting (CINV).

29 Sep 2012

BioTime forms new wholly owned subsidiary

BioTime, Inc., an Alameda-based company engaged in research and development of innovative new products in the field of regenerative medicine utilizing stem cells and related technology, announced today that it has formed a new wholly owned subsidiary, BioTime Acquisition Corporation, to pursue opportunities and acquire assets and businesses in the fields of stem cells and regenerative medicine.

29 Sep 2012

Research roundup: Saving money with hospital observation units, total knee replacement rates skyrocketing, Medicare patients and antibiotic overuse

The authors write: Using observation units in hospitals to provide care to certain patients can be more efficient than admitting them to the hospital and can result in shorter lengths-of-stay and lower costs. However, such units are present in only about one-third of US hospitals.

29 Sep 2012

Increase in rates of short telomeres predicts longevity in mammals

A team of researchers from the Spanish National Cancer Research Centre (CNIO), headed by CNIO Director Mar-a Blasco, has demonstrated in a pioneering study on mammals that longevity is defined at a molecular level by the length of telomeres. The work-which is published today in the online edition of the journal Cell Reports-opens the door to further study of these cellular components in order to calculate the rate at which cells age and thus be able to determine life expectancy for a particular organism.

28 Sep 2012

First Edition: September 28, 2012

Today's headlines include reports about political and policy-oriented health care developments.

28 Sep 2012

Cancer News and Research

Latest Cancer News and Research

New studies reveal real economic and human costs of caring for cancer patients in Europe

Synta announces results from ganetespib Phase 2b trial on NSCLC

Exelixis announces preliminary results from BRIM7 Phase Ib trial on BRAFV600 mutated MM

Study to look at whether maternal exercise during pregnancy can reduce risk of cancer in offspring

New trial data shows improvements in treatment of esophageal and gastrointestinal cancers

JAAD to publish Sensus Healthcare’s superficial radiotherapy study on non melanoma skin cancer

PLOS ONE journal releases report on validation of Falcon Genomics' Cancer BioChip System

State highlights: Free Calif. health care clinic a big draw; New Calif. law could mean mammogram alternatives

Hackensack University Medical Center announces joint venture with community physicians and USPI

Mount Sinai surgeon offers tips to prevent prostate cancer

AVEO submits tivozanib NDA with FDA for treatment of advanced renal cell carcinoma

FDA approves Abbott’s HUMIRA to treat ulcerative colitis

ACS honors world-leader in robotic prostate surgery with 2012 Community Partner Award

Wage disparities could limit success of health-care reform

1-800-Oncologist launches Contributing Expert program

A.P. Pharma resubmits APF530 NDA with FDA for prevention of CINV

BioTime forms new wholly owned subsidiary

Research roundup: Saving money with hospital observation units, total knee replacement rates skyrocketing, Medicare patients and antibiotic overuse

Increase in rates of short telomeres predicts longevity in mammals

First Edition: September 28, 2012

Understanding the DNA Damage Response in Innate Immunity eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Cancer News and Research

Latest Cancer News and Research

Understanding the DNA Damage Response in Innate Immunity eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Newsletters you may be interested in